Fig 1. HSV yields after depletion of H3 chaperones by siRNA.

(A) Immunoblot of lysates from TERT-HF cells treated with siRNA against nuclear H3 chaperones ATRX, CHAF1A, DAXX, SSRP1, DEK, ASF1A using a LiCor Odyssey imager. (B) Immunoblot of nuclear TERT-HF cells treated with siRNA against nuclear H3 chaperones HIRA, ASF1A, and ASF1B using x-ray film. Viral yields from TERT-HF cells treated with siRNAs (C) against non-targeting, ATRX, CHAF1A, DAXX, SSRP1, DEK, ASF1A, HIRA, and ASF1B. (D) Immunoblot of combinatorial siRNA treatments against ATRX, DEK, and HIRA using x-ray film († Mechanical failure of a freezer led to partial degradation of the siNon-Targeting treated sample). (E) Viral yields from TERT-HF cells treated with combinatorial siRNA treatments against ATRX, DEK, and HIRA. (F) Immunoblot of combinatorial siRNA treatments against ATRX, CHAF1A, HIRA, ASF1A, and ASF1B using x-ray film. (G) Viral yields from TERT-HF cells treated with combinatorial siRNA treatments against CHAF1A, HIRA, ATRX, ASF1A, and ASF1B which were infected with HSV 7134 at an MOI of 0.1. Viral lysates were collected at 48 hpi and titrated on U2OS cells. Yields were normalized to (PFU/mL)/1x10⁵ cells. Results were analyzed by One-way ANOVA using Dunnet’s multiple comparison correction. Data are reported as the average of 3 independent experiments ± standard error of the mean; p < 0.05 (*), p < 0.01 (**), p < 0.001 (***).